UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000012813
Receipt No. R000014967
Official scientific title of the study Phase II trial as new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer.
Date of disclosure of the study information 2014/01/20
Last modified on 2019/01/18 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Phase II trial as new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer.
Title of the study (Brief title) Phase II trial as new adjuvant chemotherapy regimen for capecitabine
Region
Japan

Condition
Condition StageII(high risk) and stageIIIa resectable colorectal cancer
Classification by specialty
Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Safety and efficacy of new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Occurrence rate of side effect
Key secondary outcomes Disease free survival, safety, proportion of treatments completed, quality of life.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Capecitabine 5-days on/ 2-days off schedule
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Histopathological diagnosis of stage II(high risk) and IIIa colorectal cancer
2.curable resection
3.more than 20 yeras old
4.ECOG Performance Status 0-2
5.WBC more than 3000/mm3,
neutrophil more than 1500/mm3,
Platelet more than 10x104/mm3,
Hb more than 9g/dL,
TBil less than 1.5mg/dL,
AST and ALT less than 100IU/L
Cr less than 1.5mg/dL,

6. it is possible to perform adjuvant chemotherapy within 8 weeks after tumor resection
7.informed consent
Key exclusion criteria 1.Pregnant female
2.It may be pregnant state female
3.Past history of malignant disease
4.There is uncontrolled cerebrovascular disease
5.There was serious allergy for fluorouracl related drug
6.There was allergy due to the lack of DPD
7.There is uncontrorable infection disease
8.It is difficult to intake oral food
9.Judgementof study controlled doctor
Target sample size 25

Research contact person
Name of lead principal investigator Tsukasa Hotta
Organization Wakayama Medical University,
School of Medicine
Division name Second Department of Surgery
Address 811-1, Kimiidera, Wakayama 641-8510, Japan
TEL 073-441-0613
Email hotta@wakayama-med.ac.jp

Public contact
Name of contact person Tsukasa Hotta
Organization Wakayama Medical University, School of Medicine
Division name Second Department of Surgery
Address 811-1, Kimiidera, Wakayama 641-8510, Japan
TEL 073-441-0613
Homepage URL
Email hotta@wakayama-med.ac.jp

Sponsor
Institute Tsukasa Hotta
Institute
Department

Funding Source
Organization Wakayama Medical University,
School of Medicine
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 01 Month 20 Day

Progress
Recruitment status Completed
Date of protocol fixation
2013 Year 12 Month 13 Day
Anticipated trial start date
2014 Year 01 Month 20 Day
Last follow-up date
2017 Year 03 Month 31 Day
Date of closure to data entry
2017 Year 03 Month 31 Day
Date trial data considered complete
2017 Year 03 Month 31 Day
Date analysis concluded
2017 Year 12 Month 31 Day

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2014 Year 01 Month 10 Day
Last modified on
2019 Year 01 Month 18 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000014967